Ceftobiprole medocaril (BAL5788) treatment of experimental Haemophilus influenzae, Enterobacter cloacae, and Klebsiella pneumoniae murine pneumonia.
Ceftobiprole (BAL9141) is an investigational cephalosporin active against methicillin- and vancomycin-resistant staphylococci administered as a water-soluble prodrug, ceftobiprole medocaril (BAL5788). Using an immunocompetent murine pneumonia model of Haemophilus influenzae, Enterobacter cloacae, or extended-spectrum beta-lactamase (ESBL) nonproducing or producing Klebsiella pneumoniae pneumonia, we compared results of treatment with ceftobiprole medocaril (71 mg/kg, sc, qid), ceftriaxone (50 mg/kg, im, bid), or cefepime (50 mg/kg, ip, q.i.d.). Results were expressed as median and 25th to 75th percentile log10 colony forming units per gram of lung tissue. Ceftobiprole, ceftriaxone, and cefepime were each more active than was no treatment and were equally active for treatment of experimental H. influenzae, E. cloacae, or ESBL-nonproducing K. pneumoniae pneumonia. For ESBL-producing K. pneumoniae, no differences were detected between no treatment and treatment with ceftobiprole, ceftriaxone, or cefepime. Ceftobiprole is active against H. influenzae, E. cloacae, and ESBL-nonproducing K. pneumoniae in an immunocompetent experimental murine pneumonia model.
Rouse
Mark S
MS
Division of Infectious Diseases, Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester, MN 55905, USA.
Hein
Melanie M
MM
Anguita-Alonso
Paloma
P
Steckelberg
James M
JM
Patel
Robin
R
D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D002511:Cephalosporins / Q000627:therapeutic use*; D024881:Drug Resistance, Bacterial / Q000187:drug effects; D016972:Enterobacter cloacae / Q000187:drug effects; D005260:Female; D006193:Haemophilus influenzae / Q000187:drug effects; D007121:Immunocompetence; D007711:Klebsiella pneumoniae / Q000187:drug effects; D051379:Mice; D023421:Models, Animal; D018410:Pneumonia, Bacterial / Q000188:drug therapy*; D018709:Statistics, Nonparametric; D014018:Tissue Distribution / Q000187:drug effects
D000900:Anti-Bacterial Agents; D002511:Cephalosporins; C443755:ceftobiprole